{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:50:49Z","timestamp":1787028649679,"version":"build-2736575974"},"reference-count":51,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Astellas Pharma, Inc."},{"name":"FibroGen, Inc."},{"name":"AstraZeneca"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved to treat anemia of chronic kidney disease (CKD). The efficacy and safety of roxadustat compared with parenteral erythropoiesis-stimulating agents (ESAs) were evaluated in patients with anemia of CKD receiving peritoneal dialysis (PD). Methods: This analysis pooled data from four phase 3, multicenter, randomized, open-label, active-comparator studies (PYRENEES, SIERRAS, HIMALAYAS, ROCKIES). The primary endpoints evaluated were hemoglobin change from baseline (CFB) to Weeks 28\u201336 without rescue therapy and hemoglobin CFB to Weeks 28\u201352 regardless of rescue therapy use. Safety data were reported. Results: This analysis included 422 patients (215 roxadustat, 207 ESA). Hemoglobin CFB to Weeks 28\u201336 without rescue therapy and hemoglobin CFB to Weeks 28\u201352 regardless of rescue therapy achieved non-inferiority for roxadustat vs. ESAs. The mean weekly dose of roxadustat was maintained over time (Weeks 1\u20134, 3.86 mg\/kg\/week; Weeks 101\u2013104, 3.27 mg\/kg\/week), whereas the mean weekly ESA dose increased by 24% (Weeks 1\u20134, 115.70 IU\/kg\/week; Weeks 101\u2013104, 143.40 IU\/kg\/week). Fewer patients treated with roxadustat received intravenous iron supplementation and rescue therapy, and patients treated with an ESA required blood transfusions sooner. Roxadustat-treated patients experienced a greater decrease in low-density lipoprotein cholesterol levels relative to baseline vs. ESA-treated patients. Treatment-emergent adverse events were similar in both treatment groups. Major adverse cardiovascular event (MACE), MACE plus unstable angina or congestive heart failure, and all-cause mortality hazard ratios were &lt;1; the lower limit of the 95% CIs was &lt;0.6, and the upper limit was &gt;1.3. Conclusions: Roxadustat was non-inferior to ESAs in correcting and maintaining hemoglobin levels, with stable dosing and a comparable safety profile, in anemic patients receiving PD.<\/jats:p>","DOI":"10.3390\/jcm13226729","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T03:53:14Z","timestamp":1731383594000},"page":"6729","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Roxadustat Efficacy and Safety in Patients Receiving Peritoneal Dialysis: Pooled Analysis of Four Phase 3 Studies"],"prefix":"10.3390","volume":"13","author":[{"given":"Danilo","family":"Fliser","sequence":"first","affiliation":[{"name":"Saarland University Medical Center, 66424 Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0996-9622","authenticated-orcid":false,"given":"Sunil","family":"Bhandari","sequence":"additional","affiliation":[{"name":"Hull University Teaching Hospitals NHS Trust, Hull York Medical School, Hull HU3 2JZ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9805-9523","authenticated-orcid":false,"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[{"name":"UAM, IIS-Fundacion Jimenez Diaz, 28015 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki","family":"Santos","sequence":"additional","affiliation":[{"name":"Astellas Pharma, Inc., Northbrook, IL 60062, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najib","family":"Khalife","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe Ltd., Addlestone KT15 2NX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Jiletcovici","sequence":"additional","affiliation":[{"name":"Astellas Pharma, Inc., Northbrook, IL 60062, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Akizawa","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo 142-8666, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3949\/ccjm.83a.15065","article-title":"Anemia of chronic kidney disease: Treat it, but not too aggressively","volume":"83","author":"Nakhoul","year":"2016","journal-title":"Cleve Clin. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000455166","article-title":"Targeting hypoxia-inducible factors for the treatment of anemia in chronic kidney disease patients","volume":"45","author":"Locatelli","year":"2017","journal-title":"Am. J. Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Dmitrieva, O., de Lusignan, S., Macdougall, I.C., Gallagher, H., Tomson, C., Harris, K., Desombre, T., and Goldsmith, D. (2013). Association of anaemia in primary care patients with chronic kidney disease: Cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data. BMC Nephrol., 14.","DOI":"10.1186\/1471-2369-14-24"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Eriksson, D., Goldsmith, D., Teitsson, S., Jackson, J., and van Nooten, F. (2016). Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia. BMC Nephrol., 17.","DOI":"10.1186\/s12882-016-0312-9"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Stauffer, M.E., and Fan, T. (2014). Prevalence of anemia in chronic kidney disease in the United States. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0084943"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.ajkd.2017.09.026","article-title":"Update on anemia in ESRD and earlier stages of CKD: Core curriculum 2018","volume":"71","author":"Fishbane","year":"2018","journal-title":"Am. J. Kidney Dis."},{"key":"ref_7","first-page":"179","article-title":"The truth on current peritoneal dialysis: State of the art","volume":"75","author":"Krediet","year":"2017","journal-title":"Neth. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrneph.2016.181","article-title":"Changes in the worldwide epidemiology of peritoneal dialysis","volume":"13","author":"Li","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.xkme.2021.01.011","article-title":"Anemia management in peritoneal dialysis: Perspectives from the Asia Pacific region","volume":"3","author":"Li","year":"2021","journal-title":"Kidney Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3324\/haematol.10985","article-title":"Anemia management in patients on peritoneal dialysis: Efficacy and safety of epoetin delta","volume":"93","author":"Spinowitz","year":"2008","journal-title":"Haematologica"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1080\/14740338.2016.1182494","article-title":"An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease","volume":"15","author":"Locatelli","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.kisu.2020.12.003","article-title":"Iron metabolism and management: Focus on chronic kidney disease","volume":"11","author":"Agarwal","year":"2021","journal-title":"Kidney Int. Suppl."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1053\/j.ajkd.2016.12.011","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibitors: A potential new treatment for anemia in patients with CKD","volume":"69","author":"Gupta","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/ckj\/sfab273","article-title":"The ERA Registry Annual Report 2019: Summary and age comparisons","volume":"15","author":"Boenink","year":"2022","journal-title":"Clin. Kidney J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.1007\/s12325-021-01903-7","article-title":"Efficacy and cardiovascular safety of roxadustat in dialysis-dependent chronic kidney disease: Pooled analysis of four phase 3 studies","volume":"38","author":"Barratt","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1007\/s12325-021-01904-6","article-title":"Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: A European phase 3, randomized, open-label, active-controlled study (PYRENEES)","volume":"38","author":"Csiky","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.ekir.2021.04.007","article-title":"A randomized trial of roxadustat in anemia of kidney failure: SIERRAS Study","volume":"6","author":"Charytan","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1093\/ndt\/gfab051","article-title":"Roxadustat for anemia in patients with end-stage renal disease incident to dialysis","volume":"36","author":"Provenzano","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2020111638","article-title":"Roxadustat versus epoetin alfa for treating anemia in patients with chronic kidney disease on dialysis: Results from the randomized phase 3 ROCKIES study","volume":"33","author":"Fishbane","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.34067\/KID.0001442022","article-title":"Changes in iron availability with roxadustat in nondialysis- and dialysis-dependent patients with anemia of CKD","volume":"3","author":"Pergola","year":"2022","journal-title":"Kidney360"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jacc.2014.12.018","article-title":"2014 ACC\/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Data Standards (writing committee to develop cardiovascular endpoints data standards)","volume":"66","author":"Hicks","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1111\/dom.13349","article-title":"The European Medicines Agency\u2019s approval of new medicines for type 2 diabetes","volume":"20","author":"Blind","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.xkme.2020.01.007","article-title":"Inflammation and erythropoiesis-stimulating agent response in hemodialysis patients: A self-matched longitudinal study of anemia management in the dialysis outcomes and practice patterns study (DOPPS)","volume":"2","author":"Karaboyas","year":"2020","journal-title":"Kidney Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/1744-9987.13609","article-title":"Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients","volume":"25","author":"Akizawa","year":"2021","journal-title":"Ther. Apher. Dial."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/1744-9987.12888","article-title":"Intermittent oral dosing of roxadustat in peritoneal dialysis chronic kidney disease patients with anemia: A randomized, phase 3, multicenter, open-label study","volume":"24","author":"Akizawa","year":"2020","journal-title":"Ther. Apher. Dial."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"i2355","DOI":"10.1093\/ndt\/gfae069.1473","article-title":"A multicenter, single-arm study of roxadustat in Chinese patients with chronic kidney disease-associated anemia receiving peritoneal dialysis [abstract 437]","volume":"39","author":"Yu","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_27","first-page":"e24427","article-title":"Safety and effectiveness of roxadustat in dialysis-dependent patients with renal anemia: A hospital-based cohort study","volume":"14","author":"Moussa","year":"2022","journal-title":"Cureus"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Hirai, K., Nonaka, H., Ueda, M., Morino, J., Kaneko, S., Minato, S., Mutsuyoshi, Y., Yanai, K., Ishii, H., and Matsuyama, M. (2021). Effects of roxadustat on the anemia and iron metabolism of patients undergoing peritoneal dialysis. Front. Med., 8.","DOI":"10.3389\/fmed.2021.667117"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jfma.2021.06.004","article-title":"Roxadustat treatment for anemia in peritoneal dialysis patients: A randomized controlled trial","volume":"121","author":"Hou","year":"2022","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ekir.2021.12.025","article-title":"Randomized study on the efficacy of standard versus low roxadustat dose for anemia in patients on peritoneal dialysis","volume":"7","author":"Yang","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"779","DOI":"10.34067\/KID.0000482022","article-title":"The role of peritoneal dialysis in different phases of kidney transplantation","volume":"3","author":"Gardezi","year":"2022","journal-title":"Kidney360"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Righini, M., Capelli, I., Busutti, M., Raimondi, C., Comai, G., Donati, G., Cappuccilli, M.L., Ravaioli, M., Chieco, P., and La Manna, G. (2022). Impact of the type of dialysis on time to transplantation: Is it just a matter of immunity?. J. Clin. Med., 11.","DOI":"10.3390\/jcm11041054"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/01.tp.0000437435.19980.8f","article-title":"Red blood cell transfusions and the risk of allosensitization in patients awaiting primary kidney transplantation","volume":"97","author":"Leffell","year":"2014","journal-title":"Transplantation"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1093\/ndt\/gft362","article-title":"Sensitization from transfusion in patients awaiting primary kidney transplant","volume":"28","author":"Yabu","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/ndt\/gfw099","article-title":"The mode of sensitization and its influence on allograft outcomes in highly sensitized kidney transplant recipients","volume":"31","author":"Redfield","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Ganz, T., Locatelli, F., Arici, M., Akizawa, T., and Reusch, M. (2023). Iron parameters in patients treated with roxadustat for anemia of chronic kidney disease. J. Clin. Med., 12.","DOI":"10.3390\/jcm12134217"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s40620-023-01849-9","article-title":"A novel scenario in the therapeutic management of anemia of chronic kidney disease: Placement and use of roxadustat","volume":"37","author":"Locatelli","year":"2024","journal-title":"J. Nephrol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","article-title":"Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: A phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study","volume":"67","author":"Provenzano","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000527835","article-title":"Updates on hypoxia-inducible factor prolyl hydroxylase inhibitors in the treatment of renal anemia","volume":"9","author":"Li","year":"2023","journal-title":"Kidney Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.ekir.2022.01.1045","article-title":"Two Phase 3 Studies on Ophthalmologic Effects of Roxadustat Versus Darbepoetin","volume":"7","author":"Sepah","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1159\/000537913","article-title":"Exacerbation of diabetic retinopathy following hypoxia-inducible factor-prolyl hydroxylase inhibitor administration: A case report","volume":"15","author":"Ariyoshi","year":"2024","journal-title":"Case Rep. Ophthalmol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Bartnicki, P. (2024). Hypoxia-inducible factor prolyl hydroxylase inhibitors as a new treatment option for anemia in chronic kidney disease. Biomedicines, 12.","DOI":"10.3390\/biomedicines12081884"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/MNH.0000000000000542","article-title":"Thyroid disease in end-stage renal disease","volume":"28","author":"Rhee","year":"2019","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"917","DOI":"10.21873\/invivo.13519","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibitors and hypothyroidism: An analysis of the Japanese pharmacovigilance database","volume":"38","author":"Tanaka","year":"2024","journal-title":"In Vivo"},{"key":"ref_45","first-page":"e61843","article-title":"Roxadustat-induced central hypothyroidism in renal anemia patients: Insights from antineutrophil cytoplasmic antibody-related vasculitis cases","volume":"16","author":"Omote","year":"2024","journal-title":"Cureus"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2410375","DOI":"10.1080\/0886022X.2024.2410375","article-title":"Roxadustat has risks of reversible central hypothyroidism in patients undergoing hemodialysis: A single-center retrospective cohort study","volume":"46","author":"Otsuka","year":"2024","journal-title":"Ren. Fail."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"100461","DOI":"10.1016\/j.dmpk.2022.100461","article-title":"Pharmacokinetic\/pharmacodynamic modeling of roxadustat\u2019s effect on LDL cholesterol in patients in Japan with dialysis-dependent chronic kidney disease and anemia","volume":"46","author":"Takada","year":"2022","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1681\/ASN.2012100987","article-title":"Randomized, controlled trial of glucose-sparing peritoneal dialysis in diabetic patients","volume":"24","author":"Li","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/ndt\/gfv247","article-title":"Icodextrin reduces insulin resistance in non-diabetic patients undergoing automated peritoneal dialysis: Results of a randomized controlled trial (STARCH)","volume":"30","author":"Andreoli","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e2991","DOI":"10.1097\/MD.0000000000002991","article-title":"Effect of icodextrin solution on the preservation of residual renal function in peritoneal dialysis patients: A randomized controlled study","volume":"95","author":"Chang","year":"2016","journal-title":"Medicine"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1093\/ndt\/gfae075","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: A document by the European Renal Best Practice board of the European Renal Association","volume":"39","author":"Stoumpos","year":"2024","journal-title":"Nephrol. Dial. Transplant."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/22\/6729\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:28:54Z","timestamp":1760113734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/22\/6729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":51,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["jcm13226729"],"URL":"https:\/\/doi.org\/10.3390\/jcm13226729","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,8]]}}}